For the quarter ending 2026-03-31, MDGL made $311,337K in revenue. -$94,391K in net income. Net profit margin of -30.32%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Product revenue, net | 311,337 | 321,083 | 287,268 | 212,802 |
| Cost of sales | 26,847 | 24,448 | 18,122 | 9,065 |
| Research and development | 108,692 | 116,268 | 174,004 | 54,081 |
| Selling, general and administrative | 268,521 | 239,976 | 209,117 | 196,858 |
| Total operating expenses | 404,060 | 380,692 | 401,243 | 260,004 |
| Loss from operations | -92,723 | -59,609 | -113,975 | -47,202 |
| Interest income | 8,243 | 9,459 | 10,308 | 8,227 |
| Interest expense | 7,819 | 14,023* | 7,451 | 3,264 |
| Gain on extinguishment of debt | - | 5,558* | -2,779 | - |
| Other expense, net | -2,092 | 40* | -293 | -42 |
| Net loss | -94,391 | -58,575 | -114,190 | -42,281 |
| Basic EPS | -3.25 | -2.552 | -5.08 | -1.9 |
| Diluted EPS | -3.25 | -2.552 | -5.08 | -1.9 |
| Basic Average Shares | 29,032,422 | 22,956,407 | 22,482,502 | 22,207,017 |
| Diluted Average Shares | 29,032,422 | 22,956,407 | 22,482,502 | 22,207,017 |
MADRIGAL PHARMACEUTICALS, INC. (MDGL)
MADRIGAL PHARMACEUTICALS, INC. (MDGL)